Total amount raised
$345M
Latest funding date
2025-11-06
Location
Synchron has raised funding across four institutional rounds totaling $345 million, with the latest being a Series D round in November 2025. The company is backed by 32+ investors, including notable names like Double Point Ventures, ARCH Venture Partners, Khosla Ventures, and Bezos Expeditions.
Synchron's innovative brain-computer interface technology aims to empower autonomy and social connection for individuals with movement limitations. Keep reading to explore the intricacies of Synchron's fundraising journey and the investors backing this groundbreaking platform.
Synchron has raised funding across four institutional rounds totaling $345 million, with the latest being a Series D round in November 2025. The company is backed by 32+ investors, including notable names like Double Point Ventures, ARCH Venture Partners, Khosla Ventures, and Bezos Expeditions.
Synchron's innovative brain-computer interface technology aims to empower autonomy and social connection for individuals with movement limitations. Keep reading to explore the intricacies of Synchron's fundraising journey and the investors backing this groundbreaking platform.
What Is Synchron?
Synchron, based in Brooklyn, New York, is a pioneering bioelectronics medicine company. Specializing in brain-computer interface (BCI) technology, Synchron develops neuromodulation solutions for previously untreatable nervous system conditions. The company operates in the fields of Information Technology, Manufacturing, Medical, and Medical Device industries.
Founded with the mission to empower autonomy and social connection, Synchron employs between 101 and 250 people. Their innovative BCI device allows users to control digital devices using their thoughts, utilizing a minimally-invasive endovascular procedure that avoids open brain surgery.
How Much Funding Has Synchron Raised?
- Series A
- Amount Raised: USD 10,000,000
- Date: April 2017
- Lead Investors: Neurotechnology Investors (NTI)
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To develop and refine their brain-computer interface (Stentrode™) technology. Participants included the U.S. Department of Defense (DARPA).
- Series B
- Amount Raised: USD 40,000,000
- Date: June 2021
- Lead Investors: Khosla Ventures
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To fund the launch of U.S. clinical trials for their brain-computer interface technology. Participants included NeuroTechnology Investors, METIS Innovative, Forepont Capital Partners, ID8 Investments, Shanda Group, General Advance, and others.
- Series C
- Amount Raised: USD 75,000,000
- Date: December 2022
- Lead Investors: ARCH Venture Partners
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To scale operations and advance research and development. New participants included Gates Frontier (Bill Gates), Bezos Expeditions (Jeff Bezos), Reliance Digital Health, Greenoaks, Alumni Ventures, Moore Strategic Ventures, and Project X.
- Series D
- Amount Raised: USD 200,000,000
- Date: November 6, 2025
- Lead Investors: Double Point Ventures
- Valuation at Round: Reported at approximately $1 billion
- Motivation Behind the Round: To advance commercialization of the Stentrode™ BCI platform and expand AI and engineering operations in New York and San Diego. New participants included Australia's National Reconstruction Fund (NRF), T.Rx Capital, Qatar Investment Authority (QIA), K5 Global, Protocol Labs, and IQT. Existing investors ARCH Ventures, Khosla Ventures, Bezos Expeditions, NTI, and METIS also participated.
Total Amount Raised: USD 345,000,000 (across all disclosed rounds). Current Valuation: Reported at approximately $1 billion at the time of Series D.
Key Investors
- Double Point Ventures
- Details: Double Point Ventures is a Boston-based venture capital firm that led Synchron's Series D round in November 2025. The firm focuses on life sciences and high-tech investments at Series B through Series D stages.
- Investment Focus Areas: Life sciences, healthcare, high technology.
- Notable Investments: Synchron, Umoja Biopharma, Cerevance, ImmunOs Therapeutics, DermBiont.
- ARCH Venture Partners
- Details: ARCH Venture Partners is a venture capital firm headquartered in Chicago, IL and Seattle, WA. They led Synchron's Series C round in December 2022 and continued participating in the Series D.
- Investment Focus Areas: Biotechnology, life sciences, physical sciences.
- Notable Investments: Illumina, Alnylam Pharmaceuticals, Twist Bioscience.
- Khosla Ventures
- Details: Khosla Ventures is a Silicon Valley-based venture capital firm founded by Vinod Khosla. They led Synchron's Series B round in June 2021 and participated in the Series D.
- Investment Focus Areas: Technology, healthcare, sustainability, consumer sectors.
- Notable Investments: Square, DoorDash, Impossible Foods, Stripe.
- Neurotechnology Investors (NTI)
- Details: Neurotechnology Investors (NTI) is an investment group drawing on over 100 neurology, neurosurgery, and radiology specialists across the U.S. They led Synchron's Series A in 2017 and have participated in all subsequent rounds.
- Investment Focus Areas: Neurotechnology, medical devices.
- Notable Investments: Synchron (across all rounds).
- Bezos Expeditions
- Details: Bezos Expeditions is the personal investment fund of Jeff Bezos. It participated in Synchron's Series C round in December 2022 and continued as an investor in the Series D.
- Investment Focus Areas: Technology, life sciences, healthcare.
- Notable Investments: Synchron, various technology and life sciences ventures.
What's Next for Synchron?
Synchron stands on the brink of transformative opportunities. With the launch of U.S. clinical trials for their Stentrode™ technology, the company aims to revolutionize the treatment of neurological conditions. This minimally invasive brain-computer interface could significantly impact patients with paralysis, epilepsy, and depression, among others. The potential market is vast, given the 60 patent applications covering various conditions.
Future fundraising appears promising as Synchron progresses through clinical trials. Success in these trials could attract substantial investments, enabling further development and commercialization. The growing interest in neurotechnology and minimally invasive medical solutions positions Synchron well for additional funding rounds and potential strategic partnerships.
However, challenges lie ahead. Regulatory hurdles, technical reliability, and competition from other BCI developers are significant obstacles. Ensuring the safety and efficacy of their technology will be crucial for gaining FDA approval and market acceptance. Despite these challenges, Synchron's innovative approach and robust patent portfolio offer a promising path forward.
Use Clay to Get Funding Data
Sales professionals, take your strategy to the next level by leveraging Clay's platform to access comprehensive fundraising data on companies like Synchron and gather other critical business insights.
Sign up for free to start unlocking valuable information that can drive your sales success.
